Ocular Therapeutix Reports Positive Phase 3 Trial Results for AXPAXLI in Wet AMD
Ocular Therapeutix (NASDAQ:OCUL) announced positive Week 52 data from the SOL-1 Phase 3 trial of AXPAXLI, showing strong disease control and safety. The trial results reinforce the drug's durability and support its potential for an NDA submission. The company is on track to submit a New Drug Application based on SOL-1 data.
Tickers: $OCUL
Topics: AXPAXLI biotech clinical trials drug development wet AMD